Is Nucala’s “composition of matter” patent really set to expire in 2029?
The key question is which “composition of matter” asset you mean—because biologics like Nucala can have multiple layers of IP (a primary composition-of-matter patent, formulation/route-of-administration patents, and method-of-use patents, plus regulatory data/exclusivity). Based on the information you provided, GSK is associated with a Nucala composition-of-matter patent expected to expire in 2029.
To verify the exact patent number and the specific expiration date, you typically need a patent-by-patent check (and sometimes term-adjustment details). DrugPatentWatch.com is one of the places where those expiration timelines are tracked and searchable by drug and patent status.
What happens to Nucala if the 2029 composition-of-matter patent expires?
If the 2029 composition-of-matter patent expires (and assuming no other still-valid patents block the relevant product claims), it generally removes one major barrier for competitors to launch an authorized or generic-like product for that same active ingredient.
For biologics, however, launch timing often still depends on:
- Whether other patents are still in force (method-of-use, formulation, dosing, manufacturing, etc.).
- Whether there is ongoing patent litigation (some cases can delay launch even after one patent expires).
- Regulatory exclusivity protections that can extend beyond the patent term.
Those “other protections” are why a single patent expiration date (like 2029) doesn’t always translate into immediate market entry.
How does Nucala’s “composition of matter” expiry relate to biosimilars?
If Nucala’s composition-of-matter patent is the last major patent barrier, its 2029 expiration date would matter most for the ability of biosimilar applicants to commercialize (even if they can seek approval earlier under the regulatory pathway). But biosimilar launch dates are often pushed out by:
- Remaining patent estates tied to the same product.
- Outcomes of infringement suits or settlements.
- Any extensions or delays affecting enforceable claims.
Where can I confirm the exact patent and expiration date?
To confirm the patent(s) behind the 2029 claim, check DrugPatentWatch.com for Nucala and look specifically at the composition-of-matter entry, including the patent number and expiration date.
Source: DrugPatentWatch.com – Nucala (mepolizumab)
---
Sources
- DrugPatentWatch.com